N- (1- (4- (5- chloro- 2- oxo- 2,3- dihydro- 1H- benzo(d)imidazol- 1- yl)piperidin- 1- yl)propan- 2- yl)- 2- naphthamide

Also Known As:

VU0155069

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Sepsis (Septicemia) 10/04/2019 - "Here, we evaluated the effects of a phospholipase D1 (PLD1)-selective inhibitor (VU0155069) against sepsis and inflammasome activation. " 10/04/2019 - "VU0155069 strongly enhances survival rate in cecal ligation and puncture (CLP)-induced sepsis by inhibiting lung inflammation, leukocyte apoptosis, and the production of proinflammatory cytokines, especially IL-1β. "
2.	Pneumonia (Pneumonitis) 10/04/2019 - "VU0155069 strongly enhances survival rate in cecal ligation and puncture (CLP)-induced sepsis by inhibiting lung inflammation, leukocyte apoptosis, and the production of proinflammatory cytokines, especially IL-1β. "
3.	Breast Neoplasms (Breast Cancer) 08/01/2017 - "Treatment with the PLD1 specific inhibitor VU0155069 sensitized MCF7 and MDA-MB-231 breast cancer cells to doxorubicin-induced cytotoxicity. "